Letters to the Editor

Extending duration of letermovir prophylaxis in haploidentical stem cell transplantation

Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California Irvine, California, USA; Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok
Department of Pharmacy, University of California Irvine Health, Orange, CA, USA; Department of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California, Irvine, California
Department of Pharmacy, University of California Irvine Health, Orange, CA, USA; Department of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California, Irvine, California
Department of Pharmacy, University of California Irvine Health, Orange, CA, USA; Department of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California, Irvine, California
Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California Irvine, California
Division of Infectious Diseases, Department of Medicine, University of California Irvine, California
Division of Infectious Diseases, Department of Medicine, University of California Irvine, California
Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California Irvine, California
Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California Irvine, California
Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California Irvine, California
Haematologica Early view Jul 11, 2024 https://doi.org/10.3324/haematol.2024.285766